Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)

The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or hepatitis B virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and ultimately, tuberculosis (TB) and HBV disease progression. * The research should focus on HIV-induced immunometabolic alterations in a host suppressed on combination antiretroviral therapy (cART-suppressed). * The research should investigate how these alterations impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mtb or HBV. * The research should define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and ultimately, TB and HBV disease progression.